As researchers rummage through a pantry of potential next-generation immunotherapies, they have developed a handful of new technologies they hope can be deployed against cancer: Natural killer cells. Neoantigen vaccines. Tumor-infiltrating lymphocytes.
Then there are T cell receptor, or TCR, therapies. In some ways, they’re similar to the CAR-T therapies that are already being used to treat some patients. But their potential to swarm and invade difficult-to-treat cancers, including solid tumors, has spurred hopes that they can significantly expand the population of patients who respond to immunotherapies.
Immunotherapies harness the power of the immune system to attack cancer cells; TCR is specifically designed to supercharge one part of the immune system: T cells.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect